Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference

DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 9:40 a.m. ET.

Rhea-AI Summary

DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 9:40 a.m. ET. An audio webcast will be accessible on the Investor Relations section of Chimerix's website, where it will be archived for about 90 days. Chimerix is focused on developing innovative medicines for serious diseases. The company recently received FDA approval for TEMBEXA, targeting smallpox, and is advancing clinical programs for ONC201 and dociparstat sodium.

Argus Session date unavailable

+4.20% session move Open Argus

Details

News Market Reaction – CMRX

The recorded move for CMRX in the trading session of this news was +4.20%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference on Monday, November 8, 2021 at 9:40 a.m. ET.

An audio webcast of the fireside chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and the results from an efficacy analysis by blinded independent central review are expected in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:

Investor Relations:                            
Michelle LaSpaluto
919-972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Chimerix presentation at the Credit Suisse Healthcare Conference?

Chimerix's CEO Mike Sherman will present on November 8, 2021, at 9:40 a.m. ET.

Where can I listen to the Chimerix conference presentation?

The audio webcast will be available on the Investor Relations section of Chimerix's website.

What recent FDA approval did Chimerix receive?

Chimerix received FDA approval for TEMBEXA, a treatment for smallpox.

What are the clinical programs Chimerix is currently working on?

Chimerix is developing ONC201 for glioma and dociparstat sodium for acute myeloid leukemia.

How long will the Chimerix webcast be available for?

The webcast will be archived for approximately 90 days after the event.